# Focal Point Pharmaceuticals, Inc.: Form D filings

Focal Point Pharmaceuticals, Inc., a pharmaceuticals company in Memphis, TN, filed 3 Form D notices with the SEC between 2013 and 2017. The latest, on January 31, 2017, reports $80,000 sold of a $80,000 offering to 2 investors.

Find out what Focal Point Pharmaceuticals, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.

- [Watch for new raises](https://specstream.ai/workspace/ask?q=Tell%20me%20when%20Focal%20Point%20Pharmaceuticals%2C%20Inc.%20files%20a%20new%20Form%20D%20or%20reports%20more%20money%20sold%2C%20with%20the%20filing&src=data-formd&kind=alert&entity=Focal%20Point%20Pharmaceuticals%2C%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Ffocal-point-pharmaceuticals-inc-1584237)
- [Get founders and investors](https://specstream.ai/workspace/ask?q=For%20Focal%20Point%20Pharmaceuticals%2C%20Inc.%2C%20find%20what%20the%20company%20does%2C%20its%20website%2C%20the%20founders%20and%20executives%20with%20their%20LinkedIn%20and%20work%20email%2C%20its%20investors%20and%20every%20funding%20round%20with%20the%20amounts%2C%20its%20headcount%20and%20any%20reported%20valuation&src=data-formd&kind=record&entity=Focal%20Point%20Pharmaceuticals%2C%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Ffocal-point-pharmaceuticals-inc-1584237)

## The full lists

This record is a row of these lists. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email.

- [Form D filings in Tennessee](https://specstream.ai/data/form-d/state/tennessee): 543 rows, by operating companies, filed since November 1, 2024, $27.15, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/state/tennessee
- [Form D filings in Pharmaceuticals](https://specstream.ai/data/form-d/industry/pharmaceuticals): 346 rows, by operating companies, filed since November 1, 2024, $17.30, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/industry/pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

## Company details from the filing

- Address: 40 S. MAIN ST., STE. 2200, Memphis, TN, 38103
- Phone: (484) 680-5222
- Industry: Pharmaceuticals
- Entity type: Corporation
- Incorporated in: Delaware
- Year incorporated: 2013
- Revenue range: Decline to Disclose
- Exemptions claimed: Rule 506(b)
- SEC identifier (CIK): 1584237

## Form D filings

| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Jan 31, 2017 | Amendment | $80,000 | $80,000 | $0 | 2 | Jan 30, 2017 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1584237/000158423717000002/0001584237-17-000002-index.htm) |
| Jan 31, 2017 | New notice | $80,000 | $80,000 | $0 | 2 | Jan 30, 2017 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1584237/000158423717000001/0001584237-17-000001-index.htm) |
| Aug 14, 2013 | New notice | $150,000 | $150,000 | $0 | 2 | Aug 12, 2013 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1584237/000158423713000001/0001584237-13-000001-index.htm) |

## Executive officers and directors named in the filing

| Name | Role | Note in the filing |
| --- | --- | --- |
| Raymond Hage | Executive Officer, Director |  |
| Gary Stevenson | Director |  |
| Gary Prosterman | Executive Officer, Director |  |

[Every Form D from the week of Jan 30, 2017](https://specstream.ai/data/form-d/week/2017-01-30) · [All recent filings in Tennessee](https://specstream.ai/data/form-d/state/tennessee) · [All recent Pharmaceuticals filings](https://specstream.ai/data/form-d/industry/pharmaceuticals)

Read from SEC EDGAR. Amount sold is what Focal Point Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).